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Abstract
Background: Tipranavir (TPV) is a recently approved nonpeptidic protease inhibitor (PI) of HIV-
1 and has been indicated for those infected with PIs-resistant HIV-1. However, in clinical practice,
whether the HIV-1 from the patients with virological failure to the regimens containing first-line PIs
remains susceptible to TPV/r may be questionable.
Methods: To assess the resistance levels to TPV of HIV-1 from patients with treatment failure to
first-line PIs, patients who experienced virological failure were tested for genotypic resistance of
HIV-1 since August 2006 in National Taiwan University Hospital. Patients were enrolled for this
analysis if their failed regimens contained > 12 weeks of atazanavir or lopinavir/ritonavir (defined
as ATV group and LPV/r group, respectively), but were excluded if they experienced both or other
PIs. The levels of genotypic resistance to TPV/r were determined by TPV mutation score.
Results: Till May 2008, 21 subjects in ATV group and 20 subjects in LPV/r group were enrolled.
The TPV mutation scores in subjects in LPV/r group were significantly higher than these in ATV
group (median, 3 vs 1, P = 0.007). 95.2% subjects in ATV group and only 45% subjects in LPV/r
group had an estimated maximal virological response to TPV/r (P < 0.001). The resistance levels to
TPV/r correlated with the duration of exposure to first-line PIs, whether in ATV or LPV/r group.
Conclusion: Cross-resistance from first-line PIs may impede the effectiveness of TPV/r-containing
salvage therapy. TPV/r should be used cautiously for patients with virological failure to LPV/r
especially long duration of exposure.
Background
Tipranavir (TPV) is a recently approved nonpeptidic pro-
tease inhibitor (PI) of HIV-1 and ritonavir (RTV)-boosted
tipranavir (TPV/r) has been indicated for treatment-expe-
rienced patients or those infected with PIs-resistant HIV-1
[1-3] thus TPV/r is only approved in highly treated
patients with a documented resistance to multiple PIs in
Taiwan.
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However, TPV shares some resistance-associated muta-
tions (such as M36I, M46L, I54V, I84V, etc) with other PIs
[4]. Thus, in clinical practice, whether the HIV-1 derived
from the patients with virological failure to the regimens
containing first-line PIs remains susceptible to TPV/r may
be questionable. RTV-boosted lopinavir (LPV/r) and ata-
zanavir (ATV) are recommended as the preferred first-line
PIs for antiretrovirals-naïve patients [5], therefore we
assessed and compared the levels of TPV resistance of HIV-
1 from patients with virological failure to the ATV or LPV/
r-containing antiretroviral regimens. Because resistance
testing is not necessarily feasible in areas where second-
line antiretrovirals are available, these data may help to
decide the adequate role and timing of initiating TPV/r-
containing salvage therapy.
Methods
Study population
Since August 2006, HIV-1-infected patients who experi-
enced virological failure were tested for genotypic resist-
ance of HIV-1 in National Taiwan University Hospital, the
major referral center for HIV/AIDS and reference labora-
tory for HIV-1 resistance testing in Taiwan. Virological
failure was defined if a confirmed HIV RNA level > 400
copies/mL after 24 weeks of antiretroviral treatment, or >
50 copies/mL after 48 weeks, or repeated detectable HIV
RNA level after prior suppression of viremia. Resistance
testing was performed while the patients were taking or
immediately (< 4 weeks) after discontinuation of the
failed regimen. Patients were enrolled for this analysis if
their failed regimens contained > 12 weeks of LPV/r or
ATV (defined as LPV/r group and ATV group, respec-
tively), and were excluded from the analysis if they expe-
rienced both of LPV and ATV, or using any antiretrovirals
more than 12 weeks prior to the first-line PIs, or if they
had a plasma HIV RNA < 1000 copies/mL. Low-dose RTV
was not counted as a separate drug. This study has been
approved by the Institutional Review Board of the hospi-
tal and informed consents have been obtained from all of
the subjects before analysis. Initiating LPV/r or ATV
depends on doctors' choice.
Genotypic resistance assay
This assay has been described previously [6]. Briefly, total
RNA was extracted from plasma using the QIAamp Viral
RNA Mini Kit (QIAGEN, CA, USA) according to the man-
ufacturer's protocol. The PCR reaction was carried out in a
final volume of 50 μL containing 20 mM Tris-HCl (pH
8.4), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM each deoxynu-
cleoside triphosphate, 0.2 μM of each specific primer, 2.5
U of platinum Taq DNA polymerase (Invitrogen Life Tech-
nologies, USA). Population-based nucleotide sequence
analysis of the PCR fragments was conducted using an
automatic sequencer (3100 Avent Genetic Analyzer, ABI,
CA, USA).
Tipranavir mutation score
We assessed the genotypic susceptibility of TPV/r by using
a unweighted tipranavir mutation score as described by
Baxter et al. in 2006 [7]. The score is determined by the
number of indicated mutations, consisting of L10V, I13V,
K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/
M/V, Q58E, H69K, T74P, V82L/T, N83D, I84V. An
increasing point was associated with a higher level of
resistance.
Statistical analysis
Statistical significance was determined using a non-para-
metric test (Mann-Whitney U test) to compare the dura-
tion of exposure to PI, and using Fisher exact test or Chi-
square test for categorical variables. Linear correlation was
evaluated by Pearson's correlation coefficient. P < 0.05
was considered statistically significant.
Results
Characteristics of subjects
From August 2006 to May 2008, a total of 41 subjects met
the criteria for this analysis: 21 subjects with virological
failure to ATV-containing regimens (ATV group; five of
them also received low-dose RTV for boosting ATV) and
20 subjects with virological failure to LPV/r-containing
regimens (LPV/r group). The CD4+ cell counts, plasma
HIV RNA, and the total duration of PI exposure at the time
of genotypic testing are similar in ATV group vs. LPV/r
group (Table 1). The percentages of subjects that had at
least one mutation listed in the TPV mutation score were
not significantly different in both groups (11/21 vs. 15/
20, P = 0.197). Among these mutations, M36I was the
most common mutation in both group (6/11 and 9/15,
respectively).
Levels of genotypic resistance to TPV/r
The TPV resistance levels in subjects in LPV/r group are
significantly higher than these in ATV group (TPV muta-
tion score, median, 3 vs 1, P = 0.007). Based on the study
of Baxter et al, TPV mutation scores of ≤ 1 were associated
with < 1 median fold change (FC) of IC50 from the wild-
type susceptibility, the scores of 4~ 7 were associated with
a median FC of 2 ~ 3.9, and the scores of > 8 were associ-
ated with a dramatic increase in median FC (> 14.7) [7].
We then compared the genotypic resistance of HIV-1 to
TPV/r between LPV/r group and ATV group by categoriz-
ing the score points into 0~ 1, 2~ 3, 4~ 7, and ≥ 8 (Figure
1a). No one in ATV group had a score ≥ 4; however,
among the 15 subjects in LPV/r group that had ≥ 1 muta-
tion listed in the score, near half (7/15) had a score ≥ 4 (0/
11 vs. 7/15, P = 0.01). These analyses showed significantly
higher levels of genotypic resistance to TPV in subjects
with virological failure with LPV/r-containing regimens.
The TPV mutation score was not significantly differentBMC Infectious Diseases 2009, 9:154 http://www.biomedcentral.com/1471-2334/9/154
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between the subjects with RTV-boosted ATV and the sub-
jects with ATV without RTV.
Estimated phenotypic resistance by fold change
Based on the Virco's algorithms, the lower and higher clin-
ical cut-offs (CCO1 and CCO2, respectively) of FC from
the wild-type susceptibility to TPV/r are 1.2 and 5.4,
respectively [8-10]. FC ≤ CCO1 indicates an estimated
maximal virological response, CCO1 < FC ≤ CCO2 indi-
cates an estimated reduced response, and FC > CCO2
indicates minimal response. The CCO of 1.2 and 5.4 are
correlated with TPV score of 2 and 8, thus the maximal
response could be estimated by TPV score ≤ 2, reduced
response by TPV score of 3-7, and minimal response by
TPV score ≥ 8 [7] (Figure 1b). The results showed 20 sub-
jects in ATV group (95.2%) and 9 subjects in LPV/r group
(45%) had a TPV mutation score ≤ 2 (20/21 vs. 9/20, P <
0.001), that indicated most subjects after virological fail-
ure with ATV/r-containing regimen and only less than half
subjects after virological failure with LPV/r-containing
regimens may had an estimated maximal virological
response to TPV/r-containing regimens
Correlation of the resistance levels to TPV/r with the 
exposure duration to first-line PIs
To know whether longer durations of exposure to PIs are
associated with higher levels of resistance to TPV/r, we
assessed the relationship between the TPV mutation
scores and the duration of exposure to first-line PIs in
these subjects with virological failure to regimens contain-
ing first-line PIs. The data showed that the TPV mutation
scores had a linear correlation with the duration of expo-
sure to first-line PIs, especially in subjects in LPV/r group
(Figure 2).
Discussion
This study showed the HIV-1 derived from the subjects
after virological failure with LPV/r-containing regimens
had a significantly higher genotypic resistance to TPV/r,
than that from the subjects after virological failure with
ATV-containing regimens, under the similar duration of
Table 1: Selected characteristics of enrolled subjects in this study
ATV/r (n = 21) LPV/r (n = 20) P value
Sex (M/F) 21/0 20/0
Age: median, range (years) 33.5, 21-45 35, 22-57 0.53
CD4 cell count at baseline: median, range (per μgL) 132, 25-367 121, 18-340 0.37
Plasma HIV RNA at baseline: median, range (copies/mL) 35200, 7500-232000 28900, 3500-356000 0.42
CD4 cell count at virological failure: median, range (per μgL) 195, 37-468 202, 65-520 0.56
Plasma HIV RNA at virological failure: median, range (copies/mL) 26500, 1500-87300 22500, 2200-67200 0.37
History of AIDS: no. (%) 14 (67) 15 (75) 0.808
Experienced to NNRTI: no. (%) 12 (57) 13 (65) 0.845
Duration of PI exposure: median, range (months) 13.2, 4.8-18 11.3, 3.5-17 0.32
Susceptibility to tipranavir Figure 1
Susceptibility to tipranavir. a. Distribution of tipranavir 
mutation score: The distribution of tipranavir mutation score 
in subjects with virological failure to antiretroviral regimens 
containing ritonavir-boosted lopinavir (LPV/r, n = 20) or ata-
zanavir (ATV, n = 21). P = 0.037 (by Chi-square test). b. Esti-
mated virological responses to tipranavir: Assessment of the 
estimated virological responses to TPV/r in patients experi-
encing virological failure to regimens containing LPV/r or 
ATV. The maximal response is estimated by TPV score <2, 
reduced response by TPV score of 3-7, and minimal response 
by TPV score ≥ 8.
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PI exposure. Furthermore, in these subjects with virologi-
cal failure to regimens containing first-line PIs, the TPV
resistance levels had a linear correlation with the duration
of exposure to ATV or LPV/r, indicating accumulation of
mutations through time. The results may indicate that the
subjects with virological failure with LPV/r-containing
regimens may less likely respond to TPV/r-containing reg-
imens, thus TPV/r may not be an ideal empirical choice
for patients with virological failure with LPV/r-containing
regimens, especially in a long duration of exposure. The
mechanisms remain to be investigated. The possible
explanation is that LPV/r has a high genetic barrier for
HIV-1 resistance; once HIV-1 develops resistance to LPV/r
in vivo, extensive levels of resistance-associated mutations
in HIV-1 protease gene could be identified [11].
Only three subjects had a TPV mutation score of ≥ 6 in
LPV/r group. This could mean that most patients on a fail-
ing LPV/r-containing regimens may just have a reduced
virological response but not necessarily virological failure
when shifted to TPV-containing salvage regimens. The
clinical success may still possibly be achieved by maximiz-
ing the number of active drugs in the background regi-
mens and improving the adherence of patients.
The study has several limitations. The reason to explain
why such high levels of resistance to TPV could be identi-
fied after virological failure to PI-containing regimens in a
short duration of PI exposure in these subjects may
include inadequate adherence or high baseline resistance.
However, the impact of medication adherence on the
resistance emergence, that may bias the interpretation for
the results, could not be quantitatively assessed in this
study. Though the resistance rate to PIs in treatment-naïve
patients has been documented to have a significant
increase in recent years in Taiwan [6], our data lack for the
baseline resistance information of these subjects to exactly
assess how many major mutations developed during the
treatment with PI-containing regimens. Among the
enrolled subjects in this study, the data of subtype distri-
bution is not complete. Thus, we can not define the
impact of subtypes on the treatment responses and emer-
gence of the resistance-associated mutations. However, it
appears that HIV-1 subtypes do not effect major differ-
ences in the response to antiretroviral therapy and in the
mutations leading to resistance [12]. The study is also lim-
ited by small case number thus the findings should be val-
idated by a large-scale randomized study.
Conclusion
The subjects with virological failure to LPV/r-containing
regimens may less likely respond to TPV/r-containing sal-
vage regimens than these with virological failure to ATV/
r-containing regimens, especially in a long duration of
exposure. Even the feasibility of resistance testing is lim-
ited, the empirical use of TPV/r should be very cautiously
in subjects with virological failure to LPV/r-containing
regimens unless resistance assay showed no or few muta-
tions associated with TPV resistance.
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